Kexing Biopharm688136.SHValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Kexing Biopharm (688136.SH) trades at a P/E of 19.50x, P/B of 2.22x, P/S of 3.36x, and a dividend yield of 1.21%.
Longitudinal percentile comparison: P/E sits at the 2nd percentile over the trailing 10Y window (vs. 4th percentile over 3Y); P/B sits at the 25th percentile over the trailing 10Y window (vs. 32nd percentile over 3Y); P/S sits at the 38th percentile over the trailing 10Y window (vs. 48th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 21st percentile within its industry and the 24th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.42%, ranking at the 96th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 23.0 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 2.42% total shareholder yield, 1.21% is paid out as dividends and roughly 1.21% is implied to come from buybacks — both channels are meaningfully in play. Kexing Biopharm operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHA: 688136 · SSE: 688136 · 688136
Want the full picture on whether Kexing Biopharm (688136.SH) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 19.50 | ||||||
| P/B (MRQ) | 2.22 | ||||||
| P/S (TTM) | 3.36 | ||||||
| Dividend Yield | 1.21% | ||||||
| Buyback + Div Yield | 2.42% |